The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors

Summary

The development of an inhibitory antibody in non-severe haemophilia A patients may aggravate the bleeding phenotype considerably. Effective treatment of bleeding episodes may be challenging, with ensuing severe complications. At present, evidence is scarce for optimal treatment of bleeding episodes in this patient group. The aim of this study was to describe the incidence and the treatment of bleeding episodes in inhibitor patients in a population-based unselected cohort of non-severe haemophilia A patients with clinically relevant inhibitors. Data were available for 100 of the 107 non-severe haemophilia A patients (factor VIII (FVIII) baseline, 2–40 lU/dl) from 29 centres in Europe and one centre in Australia who had developed a clinically relevant inhibitor between 1980 and 2011. The majority (89 %) of the patients were treated during the inhibitor period for bleeding episodes or a surgical intervention: 66 % needed treatment for bleeding episodes, at a median annual bleeding rate (ABR) of 1.1 (interquartile range (IQR) 0.1–2.5) and a median total of 2 (IQR 1–6) bleeding episodes. Compared to the median ABR before inhibitor development of 0.095 bleeds per year (IQR 0.02–0.42), the increase in ABR is more than a 10-fold. More than 90 % of the bleeding episodes were treated with only one type of product, most frequently (51 %) FVIII concentrates. This study provides the incidence of bleeding episodes and treatment choices in non-severe haemophilia A patients with inhibitors. The 10-fold increase to a median ABR of 1.1 episodes per year emphasizes the impact of inhibitor development for non-severe haemophilia A patients.

Keywords

Haemophilia A - factor VIII inhibitors - management of disease - haemostasis - bypassing agents

^* A complete list of the members of the INSIGHT study group appears in the Appendix.

• References

• 1 Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8: 421-432.
• 2 Coppola A. Treatment of hemophilia: a review of current advances and ongoing issues. J. Blood Med 2010; 183.
• 3 Peerlinck K, Jacquemin M. Mild haemophilia: a disease with many faces and many unexpected pitfalls. Haemophilia 2010; 16 (Suppl. 05) 100-106.
• 4 Hay CR, Ludlam CA, Colvin BT. et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-766.
• 5 Darby SC, Keeling DM, Spooner RJD. et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-1054.
• 6 Eckhardt CL, Loomans JI, van Velzen AS. et al. INSIGHT Study Group. Inhibitor development and mortality in non-severe hemophilia A. J Thromb Haemost 2015; 13: 1217-1225.
• 7 Astermark J, Donfield SM, DiMichele DM. et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA Novo-Seven Comparative (FENOC) Study. Blood 2007; 109: 546-551.
• 8 Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009; 113: 11-17.
• 9 Lloyd Jones M, Wight J, Paisley S. et al. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 464-520.
• 10 Negrier C, Goudemand J, Sultan Y. et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-1119.
• 11 Leissinger C, Gringeri A, Antmen B. et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-1692.
• 12 Valentino La. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010; 16: 263-271.
• 13 Konkle B, Ebbesen LS, Erhardtsen E. et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-1913.
• 14 Eckhardt CL, Van Velzen AS, Peters M. et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia a. Blood 2013; 122: 1954-1962.
• 15 Kasper CK, Aledort L, Aronson D. et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
• 16 Verbruggen B, Novakova I, Wessels H. et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
• 17 Velzen AS Van, Eckhardt CL, Hart DP. et al. Inhibitors in nonsevere haemophilia A : outcome and eradication strategies. Thromb Haemost 2015; 114: 46-55.
• 18 Gouw S, Stokhuijzen E, van Velzen A. et al. Group on behalf of the IS. Bleeding phenotype and baseline FVIII level in patients with nonsevere hemophilia A: results from the INSIGHT study. J Thromb Haemost 2015; 245.
• 19 Peerlinck K, Jacquemin M. Characteristics of inhibitors in mild/moderate haemophilia A. Haemophilia 2006; 12 (Suppl. 06) 43-47.
• 20 Haya S, Moret a, Cid a R. et al. Inhibitors in haemophilia A: current management and open issues. Haemophilia 2007; 13 (Suppl. 05) 52-60.
• 21 Franchini M, Coppola A, Tagliaferri A. et al. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39: 772-778.
• 22 Robbins D, Kulkarni R, Gera R. et al. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosup-pressive therapy. Am J Hematol 2001; 68: 184-188.
• 23 d’Oiron R, Volot F, Reynaud J. et al. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors. Semin Hematol 2006; 43: S3-9.
• 24 Giuffrida AC, Genesini S, Franchini M. et al. Inhibitors in mild / moderate haemophilia A : two case reports and a literature review. Blood Transfus 2008; 6: 163-168.
• 25 Eckhardt CL, Menke L, van Ommen CH. et al. Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930-937.